Chronic Myeloid Leukemia Symposium on Oncology Practice: Hematological Malignancies
نویسنده
چکیده
Address correspondence to Jorge E. Cortes, MD, Department of Leukemia, The University of Texas, M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Unit 428, Houston, TX 77030 (e-mail: [email protected]). Individual reprints of this article and a bound booklet of the entire Symposium on Oncology Practice: Hematological Malignancies will be available for purchase from our Web site www.mayoclinicproceedings.com.
منابع مشابه
SYMPOSIUM ON ONCOLOGY PRACTICE: HEMATOLOGI AL MALIGNANCIES Chronic Lymphocytic Leukemia: Diagnosis and Treatment
Address correspondence to Susan M. O’Brien, MD, Department of Leukemia, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Box 428, Houston, TX 77030 (e-mail: [email protected]). Individual reprints of this article and a bound booklet of the entire Symposium on Oncology Practice: Hematological Malignancies will be available for purchase from our Web site www.mayoclinicpr...
متن کاملHomoharringtonine and omacetaxine for myeloid hematological malignancies
Homoharringtonine (HHT), a plant alkaloid with antitumor properties originally identified nearly 40 years ago, has a unique mechanism of action by preventing the initial elongation step of protein synthesis. HHT has been used widely in China for the treatment of chronic myeloid leukemia (CML), acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Omacetaxine, a semisynthetic form of ...
متن کاملThe long-term outcome and efficacy of PR1/BCR-ABL multipeptides vaccination in chronic myeloid leukemia: results of a 7-year longitudinal investigation
Background: Although Imatinib has revolutionized the treatment of chronic myeloid leukemia (CML), not all patients reach complete remission and a considerable proportion of the patients develop resistance to Imatinib. Material and Methods: In an attempt to increase the tail on the survival curve, we conducted a Phase I/II study of PR1/BCR-ABL multipeptides vaccination trial in CML patients wit...
متن کاملAtypical myeloproliferative disorders: diagnosis and management.
Myeloid disorders constitute a subgroup of hematological malignancies that is separate from lymphoid disorders. The World Health Organization system for classification of tumors of the hematopoietic system divides myeloid disorders into acute myeloid leukemia and chronic myeloid disorders based on the presence or absence, respectively, of acute myeloid leukemia--defining morphological and cytog...
متن کاملThe role of microRNA in acute/chronic, myeloid/lymphocytic leukemia
MicroRNAs are small, non-coding sequences that regulate gene expression by inducing degradation or translational inhibition of target mRNAs. These molecules control many intracellular physiological and pathological processes.Abnormal expression of these moleculs has been described in different cancers including hematopoietic cancers. According to the type of cancer and the stage, miRNA’s expres...
متن کامل